BACKGROUND:: Men with locally advanced prostate cancer (LAPCa) or regionally advanced prostate cancer (RAPCa) are at high risk for death from their disease. Clinical guidelines support multimodal approaches, which include radical prostatectomy (RP) followed by radiotherapy (XRT) and XRT plus androgen deprivation therapy (ADT). However, there are limited data comparing these substantially different treatment approaches. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, this study compared survival outcomes and adverse effects associated with RP plus XRT versus XRT plus ADT in these men. METHODS: SEERMedicare data were queried for men with cT3-T4N0M0 (LAPCa) or cT3-T4N1M0 (RAPCa) prostate cancer. Propensity score methods were used to balance cohort characteristics between the treatment arms. Survival analyses were analyzed with the Kaplan-Meier method and Cox proportional hazards models. RESULTS: From 1992 to 2009, 13,856 men (≥65 years old) were diagnosed with LAPCa or RAPCa: 6.1% received RP plus XRT, and 23.6% received XRT plus ADT. At a median follow-up of 14.6 years, there were 2189 deaths in the cohort, of which 702 were secondary to prostate cancer. Regardless of the tumor stage or the Gleason score, the adjusted 10-year prostate cancer-specific survival and 10-year overall survival favored men who underwent RP plus XRT over men who underwent XRT plus ADT. However, RP plus XRT versus XRT plus ADT was associated with higher rates of erectile dysfunction (28% vs 20%; P = .0212) and urinary incontinence (49% vs 19%; P < .001). CONCLUSIONS: Men with LAPCa or RAPCa treated initially with RP plus XRT had a lower risk of prostate cancer-specific death and improved overall survival in comparison with those men treated with XRT plus ADT, but they experienced higher rates of erectile dysfunction and urinary incontinence. KEYWORDS: combined modality therapy, comparative effectiveness, hormone therapy, outcomes, population and observational studies, prostate cancer, radiation, surgery, survival.
INTRODUCTION
Despite widespread prostate-specific antigen (PSA)-based screening, at least 10% of men will have locally advanced prostate cancer (LAPCa) or regionally advanced prostate cancer (RAPCa) at the time of diagnosis. [1] [2] [3] Unlike men with localized prostate cancer, for whom the 5-year relative survival rate approaches 100%, 3 men with LAPCa (T3-T4N0M0) or RAPCa (T3-T4N1M0) are at increased risk for PSA failure, the need for secondary therapy, metastatic progression, and death from prostate cancer. 4 Treatment approaches vary within this high-risk group of men, and the optimal initial treatment for these patients remains undetermined and widely debated. LAPCa and RAPCa represent a heterogeneous population of tumors with varying risks of PSA failure and distant metastatic potentials after treatment. Although monotherapy alone may adequately control a subset of these cancers, clinical practice guidelines generally support multimodal treatment approaches, which include radical prostatectomy (RP) followed by adjuvant radiotherapy (XRT) and primary XRT with adjunctive androgen deprivation therapy (ADT). 4, 5 To our knowledge, little comparative data in the form of well-controlled or
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We present a population-based comparative effectiveness study of RP plus XRT versus XRT plus ADT in men with LAPCa and RAPCa to examine differences in prostate cancer-specific survival and overall survival. As a secondary endpoint, the prevalence of treatment-associated adverse events in the RP plus XRT group versus the XRT plus ADT group was evaluated.
MATERIALS AND METHODS

Data Sources
The study cohort comprised patients from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, which links patient demographic and tumor-specific data collected by SEER cancer registries to health care claims for Medicare enrollees. Information on incident cancer cases was available from 17 affiliated cancer registries from January 1, 1992, through December 31, 2009 ; the registries covered 28% of the US population, and the data were linked to Medicare claims through 2010. Greater California, Kentucky, Louisiana, and New Jersey case contributions began in 2000. 6 SEER registries collect data on each patient's cancer site, extent of disease, histology, date of diagnosis, and initial treatment. We staged patients according to the American Joint Committee on Cancer criteria. 7 The Medicare program provides health care benefits to 97% of the US population 65 years old or older. Hospitalization information for those eligible for Medicare Part A is available from the Medicare Provider Analysis and Review files. Outpatient and physician/supplier Medicare files for services rendered in physicians' offices and hospital outpatient departments are available for the 96% of Medicare beneficiaries who elect Part B coverage. Approximately 94% of SEER patients who are 65 years old or older have been successfully linked with their Medicare claims. 8 This study was deemed exempt from review by the institutional review board at the Rutgers Cancer Institute of New Jersey.
Study Population
From 1992 to 2009, 648,042 patients were diagnosed with prostate cancer. Men were excluded if they had a history of previous malignancy (n = 60,770); clinical stage T1 or T2, in situ, or M1 disease (n = 561,093); distant lymph node involvement (n = 1284); an age at diagnosis less than 65 years (n = 6646); HMO coverage during the 6 months subsequent to the diagnosis (n = 315); and no Part A or B Medicare coverage during the 6 months subsequent to the diagnosis (n = 426). After the further exclusion of those men whose treatments could not be classified and those who received primary chemotherapy (n = 3652), 13,856 men composed the final analytic cohort.
Definition of Variables
Sociodemographic, clinical, and treatment-related variables were derived from their respective data sources from the SEER-Medicare database. Patient comorbidity was categorized according to Romano et al's modification of the index 9 developed by Charlson et al, 10 and this was analogous to the methods described and used in prior studies.
11
Primary treatment was categorized according to the following 2 treatment groups: RP with adjuvant XRT and XRT with adjunctive ADT. Men who underwent surgical therapies not considered curative (eg, cryotherapy, subtotal prostatectomy, and transurethral resection of the prostate) were excluded from the RP group. To differentiate between neoadjuvant and adjuvant therapies, both SEER codes noting a radiation sequence with surgery and Medicare claims detailing the dates on which therapies were delivered were used. Adjuvant XRT was defined as XRT received within 6 months after the date of RP. XRT plus ADT was defined as XRT plus any ADT delivered 2 months before XRT until any time 3 years after XRT.
Complications associated with therapy were identified with diagnostic (International Classification of Diseases) and Current Procedural Terminology (Healthcare Common Procedure Coding System) codes from Medicare claims, which are detailed in the supporting information. Complications were evaluated as adverse effects occurring within the 12 months after primary treatment delivery.
Because the quality of PSA data captured in SEER has come into question, 12 we performed sensitivity analyses to determine the impact of its inclusion or exclusion in our study. The inclusion or exclusion of PSA in our analyses did not significantly alter our overall findings. Therefore, all data shown include analyses excluding the PSA variable.
Statistical Analysis
The primary study endpoints were prostate cancer-specific survival and overall survival according to the cancer
Cancer October 15, 2018 stage, Gleason score, and treatment received. Secondary study endpoints assessed the prevalence of treatment-related complications according to treatment. Propensity score methods were used to balance patient characteristics between groups and to control for observed confounding factors. The propensity score was estimated from a logistic regression model of the probability of RP plus XRT with respect to XRT plus ADT as a function of clinical and demographic characteristics. The covariates included age, comorbidity status, primary tumor stage, nodal stage, tumor grade, year of diagnosis, marital status, ethnicity, race, SEER region, population-of-residence quartile, income quartile, urban residence, and educational attainment quartile. Standardized mortality ratio weighting (SMRW) was used, and SMRW assigned a weight of 1 for RP plus XRT and a weight of propensity score/(1 -propensity score) for XRT plus ADT. Propensity score-adjusted (SMRW) hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. To further reduce residual confounding by controlling for proxies of unmeasured confounders, we applied a high-dimensional propensity score adjustment 13 by empirically identifying candidate dichotomous covariates from the International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code, Healthcare Common Procedure Coding System procedure code, and ICD-9 surgery code within 1 year before the cancer diagnosis. High-dimensional propensity score was estimated from a logistic regression model of the probability of RP plus XRT with respect to XRT plus ADT as a function of clinical and demographic characteristics and the empirical covariates.
The Kaplan-Meier method was used to determine 10-year prostate cancer-specific survival and 10-year overall survival. Adverse effects from treatment were ascertained from Medicare claims, and chi-square testing was used to examine the association between each adverse event and treatment.
All analyses were 2-tailed and were conducted with SAS 9.1 (SAS Institute, Inc, Cary, North Carolina). A P value < .05 was considered statistically significant.
RESULTS
Baseline Characteristics and Relation to Treatment
Of the 13,856 men diagnosed as having LAPCa or RAPCa, approximately 50% received a single intervention, with 20.8% (n = 2884), 18.3% (n = 2541), and 11.2% (n = 1545) undergoing treatment with RP alone, XRT alone, and ADT alone, respectively. Almost 30% of men received multimodal treatment, with 6.1% (n = 848) and 23.6% (n = 3272) receiving RP plus XRT and XRT plus ADT, respectively. Among men who received adjuvant XRT after RP, 29.8% (n = 253) received concurrent ADT. Finally, 20% of men (n = 2766) received no treatment within 6 months of their diagnosis.
Older men, those with more comorbid conditions, unmarried men, and those diagnosed in more contemporary eras were more likely to receive XRT plus ADT versus RP plus XRT (Table 1) . For example, among men who received RP plus XRT and men who received XRT plus ADT, >55.7% and 26.7%, respectively, were 65 to 69 years old; 9.6% and 26.1%, respectively, were 75 to 79 years old; and <1.3% and 13.5%, respectively, were 80 years old or older (P < .0001). Moreover, 90.1% and 79.2%, 7.8% and 13.7%, and 2.1% and 7.1% with comorbidity index scores of 0, 1, and ≥2, respectively, received RP plus XRT and XRT plus ADT (P < .0001). The proportion of men undergoing RP plus XRT decreased significantly over time from 9.4% in 1992-1997 to 4 .0% in 2004-2009 (P < .001). Conversely, the proportion of men receiving XRT plus ADT increased more than 3-fold from 11.6% in 1992-1997 to 37 .8% in 2004-2009 (P < .001).
The tumor stage and the Gleason score were associated with the treatment received. Men whose cancers extended beyond the prostatic capsule (T3aN0M0) or invaded the seminal vesicles (T3bN0M0) but did not involve regional lymph nodes were more likely to undergo RP plus XRT. The observed treatment pattern was independent of regional lymph node involvement because men with regional nodal metastasis and extracapsular extension (T3aN1M0) or seminal vesicle invasion (T3bN1M0) were also more likely to have undergone RP plus XRT than XRT plus ADT (T3aN1M0 disease, 5.1% undergoing RP plus XRT vs 2.0% undergoing XRT plus ADT; T3bN1M0 disease, 5.9% undergoing RP plus XRT vs 1.5% undergoing XRT plus ADT; P < .001). Patients with tumor fixation to adjacent structures (T4N0M0) were more likely to undergo XRT plus ADT versus RP plus XRT (7.1% vs 6.1%; P < .001).
Survival Analysis
At a median follow-up of 14.6 years, there were 2189 deaths in the cohort, of which 702 were secondary to prostate cancer. Without adjustments for other variables, men who received RP plus XRT were less likely to die of prostate cancer and less likely to die of any cause in comparison with those who received XRT plus ADT. These findings were independent of the primary Cancer October 15, 2018 .9665
North Central Abbreviations: ADT, androgen deprivation therapy; ITPW, inverse probability treatment weighting; RP, radical prostatectomy; SEER, Surveillance, Epidemiology, and End Results; SMRW, standardized mortality ratio weighting; XRT, radiotherapy.
a
The population of county residence, educational level, and median income were based on census-tract data (year 2000) if they were available. Otherwise, data from the zip code of residence (year 2000) were used, and they were followed by census-tract data (year 1990 with an adjustment for the year 2010) if zip code data were unavailable. Table 2 ). Adjusted Kaplan-Meier prostate cancer-specific survival and overall survival curves for the study cohort according to the tumor stage are shown in Fig. 1A ,B, respectively. Adjusted 10-year prostate cancer-specific survival and 10-year overall survival probabilities for the entire cohort according to the tumor stage and treatment are shown in Table 3 . The 10-year actuarial disease-specific survival rates for men undergoing RP plus XRT and men undergoing XRT plus ADT were 88.9% and 74.2% (survival difference, 14.7%; 95% CI, 11.4%-17.2%), respectively, with T3a/bN0-NXM0 disease; 75.7% and 58.6% (survival difference, 17.1%; 95% CI, -0.8% to 34.2%), respectively, with T3a/bN1M0 disease; and 72.0% and 60.5% (survival difference, 11.6%; 95% CI, 0.8%-16.9%), respectively, with T4N0-NXM0 disease. The 10-year actuarial overall survival rates for men undergoing RP plus XRT and men undergoing XRT plus ADT were 64.2% and 48.3% (survival difference, 15.8%; 95% CI, 11.3%-20.2%), respectively, with T3a/bN0-NXM0 disease; 44.3% and 40.5% (survival difference, 3.8%; 95% CI, -10.8% to 22.5%), respectively, with T3a/bN1M0 disease; and 49.6% and 34.9% (survival difference, 14.7%; 95% CI, -0.1% to 30.5%), respectively, with T4N0-NXM0 disease.
Adverse Outcomes by Treatment
In a propensity-adjusted analysis (Table 4) , men undergoing RP plus XRT versus XRT plus ADT were more often diagnosed as having urinary incontinence (49.1% vs 19.4%; P < .0001) and erectile dysfunction (28.3% vs 20.4%; P = .0212) and more oftentimes underwent procedures to address urinary incontinence (12.4% vs 1.6%; P = .0007) or erectile dysfunction (8.4% vs 3.7%; P = .0186). Also, men who received RP plus XRT were more often diagnosed with bladder neck contractures (BNCs; 37.6% vs 18.3%; P < .0001) and more oftentimes required procedures to address BNC (34.3% vs 12.8%; P < .0001) in comparison with those undergoing XRT plus ADT. The need to undergo procedures for urinary retention was higher in the XRT plus ADT group.
No statistically significant differences were observed between the 2 treatment groups in rates of hematuria, radiation cystitis, rectal bleeding, urinary or gastrointestinal fistulas, or radiation proctitis.
In patients who received XRT plus ADT, we did not observe higher rates of cardiovascular, metabolic, or musculoskeletal morbidity in comparison with men who received RP plus XRT. More specifically, rates of acute myocardial infarction, sudden cardiac death, coronary artery disease, thromboembolic events, skeletal fractures, Cancer October 15, 2018 Cancer October 15, 2018 and osteoporosis did not differ significantly between the 2 groups. Results of adjusted analyses comparing adverse outcomes were generally consistent with results of unadjusted analyses (data not shown).
DISCUSSION
Although several contemporary studies in various settings have shown that men with high-risk disease characteristics may have a lower risk of metastatic progression and prostate cancer-specific death after RP in comparison with other treatment modalities, 14, 15 the surgical treatment of patients with high-risk prostate cancer, defined in our study as locally advanced (cT3-T4N0M0) or regionally advanced disease (cT3-T4N1M0), has traditionally been discouraged, in part because patients are at increased risk for positive surgical margins or distant relapse, and the procedure can be technically challenging. 16, 17 As a result, primary XRT with ADT has traditionally been offered to these men despite the National Comprehensive Cancer Network and European Association of Urology/ European Society for Radiotherapy and Oncology guidelines on prostate cancer, which support both XRT plus ADT and RP plus XRT as appropriate modalities. 4, 5 More recently, there has been renewed interest in surgery for this group of men because emerging retrospective series have shown durable intermediate-to longterm cancer-specific survival and overall survival. [18] [19] [20] [21] A recent population-based study comparing the outcomes of men with LAPCa undergoing single-modality primary treatment with either RP or external-beam radiation Abbreviations: ADT, androgen deprivation therapy; RP, radical prostatectomy; XRT, radiotherapy.
Cancer October 15, 2018 found significant differences in toxicity and survival, with survival outcomes more favorable in the RP group. 22 The theoretical benefits of RP as first-line treatment are tumor volume reduction and optimal local control. Furthermore, the evaluation of prostatectomy and nodal specimens and postoperative PSA levels allow for more accurate staging and risk stratification that will better select for men who may benefit from adjuvant treatment. 23 Cancer-specific survival rates for men with clinical stage T3N0M0 prostate cancer at 10 and 15 years ranging from 85% to 92% and from 62% to 84%, respectively, have been reported. [18] [19] [20] [21] 24, 25 A few cohort studies provide survival data for surgery of clinical stage T3b-T4N0M0 prostate cancer, and they report 10-year cancer-specific and overall survival rates of 87% to 92% and 65% to 71%, respectively. 16, 26, 27 Finally, limited data evaluating the role of RP in clinically node positive (cN+) patients exist. In a recent study comparing the outcomes of 50 men with cN+ disease and 252 men with pN1 disease, a subset of men with cN+ disease experienced clinical outcomes similar to those of men with normal preoperative imaging (cN0) in the setting of lymph node metastasis. 28 Our observational analysis was aimed at determining which initial multimodal approach for highrisk prostate cancer was associated with improved survival outcomes. Several key findings were observed. First, nonadherence to practice guidelines was seen. Although National Comprehensive Cancer Network and European Association of Urology/European Society for Radiotherapy and Oncology guidelines recommend multimodal treatment for men with high-risk prostate cancer, 4, 5 approximately half the entire study cohort of 13,856 men received a single intervention, and almost 20% (n = 2766) did not receive treatment. For those receiving multimodal treatment, XRT plus ADT was most commonly delivered (23.6%), and it was followed by RP plus XRT (6.1%). Not surprisingly, patient age, comorbid conditions, and cancer stage were associated with the treatment received. For instance, men who were younger and had fewer comorbid conditions and whose cancers exhibited extracapsular extension (T3aN0M0) or seminal vesicle invasion (T3bN0M0) without regional lymph node involvement were more likely to receive RP plus XRT. Men with regional lymph node involvement and extracapsular extension or seminal vesicle invasion were also more likely to have undergone RP plus XRT than XRT plus ADT. Older men, those with more significant comorbid conditions, and those with tumor fixation to adjacent structures (cT4) were more likely to receive XRT plus ADT. These findings may be attributable to biases in the choice of treatment based on a patient's clinical stage or also in part to pathologic stage information being more accurately captured for surgically treated patients than those treated by primary XRT plus ADT.
Second, men who received primary RP followed by postsurgery XRT were less likely to die of prostate cancer and experienced improved overall survival in comparison with those who received XRT plus ADT. These findings were independent of the primary tumor stage, nodal stage, or Gleason score, although the survival advantage benefited those men without lymph node metastasis most. These data suggest that even men with high-risk disease that is not clinically localized can achieve durable long-term cancer-specific survival and overall survival with multimodal treatment, with adjusted 10-year prostate cancer-specific survival rates for men with T3a/ bN0M0 disease, T3a/bN1M0 disease, and T4N0M0 disease of 88.9%, 75.7%, and 72%, respectively, for those who received RP plus XRT and 74.2%, 58.6%, and 60.5%, respectively, for those who received XRT plus ADT. Most men with T4N1M0 disease, regardless of the treatment received, died of disease by 10 years. Although we found RP as a primary intervention to be associated with more favorable survival outcomes than XRT in this high-risk population, the questions, as other investigators have suggested, should focus not on which modality is best but instead on optimizing treatment sequences and timing, optimizing intensities of treatment, and integrating more effective systemic therapies with optimal local treatments. 29 Finally, men who underwent RP plus XRT had higher rates of erectile dysfunction (28% vs 20%), higher rates of urinary incontinence (49% vs 19%), and higher rates of BNCs and urethral strictures (38% vs 18%) in comparison with those who underwent XRT plus ADT. Anastomotic strictures are the most commonly reported complication after RP. 30 BNC and urethral stricture rates in men undergoing RP plus XRT appeared high in our study. There are several reasons that this may be. First, published rates of BNCs and/or urethral strictures after RP alone for men with clinically localized prostate cancer range widely in the literature (2.7%-26% of cases), depending on how and where the data were collected, the definition of what constitutes a stricture, and differences in surgical volume. [30] [31] [32] [33] For example, the lowest published rates of BNC (2.7%-5%) have been reported with physician-assessed definitions in academic practices. 33 Data from CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor), which enrolls patients from 43 community urology practices, academic Cancer October 15, 2018 medical centers, and Veterans Affairs hospitals throughout the United States, show a BNC rate of 8.4%. 31 Data from population-based sources (SEER-Medicare data) show BNC rates in the literature ranging from 17% to 26%. 32, 34 Even among surgeons with high RP volumes (>60/y), a BNC rate of 22% was reported with claims data from Medicare beneficiaries. 30 Our study reveals the BNC and/or urethral stricture rate after RP plus XRT to be 37.6%, with 34.3% requiring a procedure to manage the BNC and/or urethral stricture. The use of Medicare claims to identify the incidence of treating urethral strictures that occur after RP has been found to be reliable and has demonstrated excellent sensitivity, specificity, and positive predictive values. 34 The diagnostic codes and procedure codes used in our study are analogous to what has been previously published in the literature (see the supporting information). 32 Because men in our RP plus XRT cohort had high risk factors for BNC/stricture formation in comparison with men with clinically localized prostate cancer, namely more advanced disease, the receipt of adjuvant XRT, an age of 65 years or older, all risk factors for BNC and stricture formation, it is not surprising that BNC/stricture rates were higher in our study. Finally, although several published series have focused on BNCs only, we defined and evaluated strictures in any location that required treatment as an event.
No significant differences were observed in rates of hematuria, radiation cystitis, or proctitis. Although several studies have reported an association between ADT and an increased risk of myocardial infarction and cardiovascular events, metabolic syndrome, and fractures, [35] [36] [37] we did not observe higher rates of acute myocardial infarction, sudden cardiac death, osteoporosis, or fractures in men receiving XRT plus ADT versus RP plus XRT. However, our study was not designed to assess adverse effects of ADT in comparison with other treatment modalities.
Several limitations of our study warrant mention. First, our findings should be interpreted within the limitations of an observational study design. Because our patients were not randomized, the 2 treatment groups may have differed in measured and unmeasured ways that are associated with differences in survival despite our best efforts to rigorously adjust for confounders. Our propensity score analyses used information from all measured covariates to balance observed factors between treatment groups. Although propensity score analysis can also reduce the bias associated with unobserved factors, so long as relations between unobservable and measured factors exist, there are likely to be unmeasured confounding and selection biases that we were not able to control for that may have accounted for a portion of the survival differences observed in our study, as has been reported in other studies using cancer registry data. 38, 39 To further reduce residual confounding by controlling for proxies of unmeasured confounders, we also applied a high-dimensional propensity score adjustment. 13 In an attempt to further balance observed and unobserved characteristics between treatment groups beyond what is possible with propensity score adjustments, we explored the possibility of using instrumental variable analysis. 40 However, an acceptable instrument could not be identified because there was not sufficient variation in the use of XRT plus ADT in our study cohort.
Second, administrative claims are designed for billing purposes. Thus, key information that may influence outcomes, such as the radiation dosage, the field included within the radiation portal, or whether or not nerve-sparing was performed during surgery, is not precisely captured. A contemporary study of men with highrisk prostate cancer using the National Cancer Data Base found that among 14,817 patients undergoing primary radiation, 51.3% received whole pelvic XRT, whereas 48.7% received prostate-only XRT. 41 On the basis of this study and prospective randomized studies evaluating the radiation portal (ie, whole pelvic vs prostate only) in men with high-risk prostate cancer, whole pelvic XRT does not appear to be associated with an overall survival advantage in comparison with prostate-only XRT. [41] [42] [43] Also, whether XRT was delivered for adjuvant or salvage intent could not be determined from Medicare claims. To minimize the inclusion of men receiving salvage XRT, we defined adjuvant XRT strictly as XRT being delivered within 6 months after surgery. 44 Third, measuring complications of cancer treatment with Medicare claims may result in a relatively crude estimate of treatment-related adverse effects. These codes may lack clinical specificity and may not always be adequate to identify diagnoses or procedures related to complications. Because physician reimbursement is dictated by procedures rather than diagnoses, complications that are not procedurally based may risk being underreported. Also, cancer patients can experience complications that negatively affect the quality of life for which they do not seek treatment. 34 Finally, controlling the impact that concurrent technological advances in surgery and radiation have had on treatment outcomes over time is not possible with Medicare claims.
Cancer October 15, 2018 In summary, although our results are limited by the usual biases of an observational study design, men with LAPCa or RAPCa who received primary RP with postsurgery XRT had a lower risk of death from prostate cancer and had improved overall survival in comparison with those treated with primary XRT plus ADT. Men who received RP plus XRT had higher rates of erectile dysfunction (28% vs 20%; P = .0212) and higher rates of urinary incontinence (49% vs 19%; P < .001) than those who received XRT plus ADT. These findings should be verified with prospective trial data and suggest the need to include a surgical arm in future trials for men with high-risk prostate cancer.
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